设为首页收藏本站

中国病毒学论坛|我们一直在坚持!

 找回密码
 立即注册

QQ登录

只需一步,快速开始

搜索
热搜: 活动 交友 discuz
查看: 2018|回复: 5
打印 上一主题 下一主题

疫苗学《Vaccines》——6th Edition by (美)普洛特金

[复制链接]

1067

帖子

1032

学分

1万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1032
QQ
跳转到指定楼层
楼主
发表于 2015-7-25 14:07:34 | 只看该作者 回帖奖励 |倒序浏览 |阅读模式

3 I$ u( X: M3 {! |
Vaccines, 6th Edition

4 F8 l" c- E* z# j# S: zApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.5 j" C$ ], e8 t* ^" \* [" v

! n# D$ i' X* Y1 I& h8 T
http://yun.baidu.com/share/link?shareid=2079860221&uk=38109966064 j6 _' S. o8 `- U7 `, T: |8 z. i1 @

& |0 ]3 ]* q  Q* `SECTION 1: General aspects of vaccination, e3 ~9 V2 Y  m# {) I
1 A short history of vaccination 1" [) [" L/ j5 R# }
2 Vaccine immunology 14
" S4 {: i7 @; {1 w' r# A. ^# K" D3 The vaccine industry 33" P1 N, G  H2 Y' i
4 Vaccine manufacturing 44
7 s& i8 i2 U6 O7 }+ o5 Evolution of adjuvants across the centuries 58
3 c0 ?* @% p! d6 R- q4 w: X" x& b/ n6 Vaccine additives and manufacturing residuals in the United States:
: G/ ~5 a' E0 a* q# U0 h# `+ K4 @licensed vaccines 71
6 K+ e$ F% W" Z- W0 F/ j2 c4 M) J7 Passive immunization 80
% O* }8 z! F& p8 g8 General immunization practices 886 t1 F. z8 w+ a& D* j
SECTION 2: Licensed vaccines
) a3 z* h0 s: k6 h- k9 Adenovirus vaccines 113, ^; J1 }; S8 ~  O& L
10 Anthrax vaccines 127
  ^7 w8 T1 ]# {2 V/ E11 Cholera vaccines 141
& e6 Y3 ?2 k' {  z7 k+ C7 }12 Diphtheria toxoid 153  q* o+ [; f1 \& \4 s
13 Haemophilus influenzae vaccines 1677 q# H2 V/ Q0 E+ V& r
14 Hepatitis A vaccines 183" u2 ?" }- G* T# H. {# Q' Y
15 Hepatitis B vaccines 205' C' x4 G9 X* ^8 \
16 Human papillomavirus vaccines 235  n3 x" k% g, Z3 h- l
17 Inactivated influenza vaccines 257
* O1 Z5 D/ x; L+ w2 v6 z& @18 Influenza vaccine-live 294
) f; P- o  P% \! `9 T19 Japanese encephalitis vaccines 3120 C1 S5 A: A  r1 k9 {% C
20 Measles vaccines 352
# X( l* Q( u/ i2 L4 c1 ^* a3 K% G, f21 Meningococcal vaccines 388
7 W  f1 G& h1 K* @) |$ W22 Mumps vaccine 419
$ c8 `0 L1 Z& n$ N3 E  F( |23 Pertussis vaccines . 447
: s8 V9 I8 w4 ^/ }8 ^. |24 Plague vaccines 493/ q5 D( ?% `& N/ U( ~
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
) f8 W% k' _: [* ]8 Y' P# z( k7 x, ~26 Pneumococcal polysaccharide vaccines 542
5 p- M6 ?8 _* q: V& Q5 {/ w27 Poliovirus vaccine-inactivated . 573
! P% C$ Q* ]7 t( ~3 Z- s28 Poliovirus vaccine-live 598
" p3 l6 F0 q3 @+ E$ X4 i29 Rabies vaccines .6469 k8 P. o: C8 @& V
30 Rotavirus vaccines . 6695 v- A8 I6 C# k* W. h
31 Rubella vaccine 688% ?1 c# O( d0 n* e$ P! K% m
32 Smallpox and vaccinia 718
6 o% t+ g# Q) h+ E- w, h33 Tetanus toxoid 746& m$ e$ b+ }; K! n7 G
34 Tick-borne encephalitis virus vaccines 773# G  V  ]7 E- a/ V% ?' r
35 Tuberculosis vaccines 789
, j. g6 i1 Y6 V! S+ i% j36 Typhoid fever vaccines 812
' D7 v! p2 s: h( E2 L) J2 y1 |5 B/ `, K1 Y37 Varicella vaccine 837  P% p  a+ z' S3 ?0 c
38 Yellow fever vaccine 870# f, }6 O4 ?  z" n
39 Zoster vaccine 969
6 D4 V# O6 M8 x+ A1 r8 b# U! w40 Combination vaccines 981* f+ Z  y' X% L" n
SECTION 3: Vaccines in development and new vaccine strategies
5 e, ~6 D' d: h- J+ G$ w6 r41 Biodefense and special pathogen vaccines 1008* z5 `' X  @  h' A- M1 T. D
42 Therapeutic cancer vaccines 1018
0 f3 F5 A4 u4 N' X9 h43 Cytomegalovirus vaccines 1032
% `+ B5 P1 a$ C0 C& Q+ R44 Dengue vaccines 1042
7 }6 q# i! @( Q/ J3 N! P+ m45 Diarrhea caused by bacteria 10529 N3 d( M( ]1 x3 t  m! u
46 Ebola vaccine 1060
9 Z6 J+ Y; \& M; g- c47 Epstein-Barr virus vaccines 1068# n7 g' T$ V% |% i0 W& P
48 Hepatitis C vaccines 1074
: ~% R$ _' _" R$ i' q9 N  f49 Hepatitis E vaccines 1085
* h( E7 U8 @1 U/ _/ L; Q& c6 ?; w50 Herpes simplex virus vaccines 1090
! ]8 l/ w7 u% G% U" f51 Human immunodeficiency virus vaccines 10970 y) I+ W, {4 N! G
52 Lyme disease vaccines 1122
  U, B8 [1 g) V- G; i53 Malaria vaccines 1133
) x. N- B& r8 X3 L  t  ?7 _54 Noninfectious disease vaccines 1138+ Q: M2 M' D3 M. ?. v
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
5 _  i+ D, ]2 {- s+ J0 b56 Parasitic disease vaccines 11546 t4 Y3 E  o5 {5 ^% _1 E' X
57 Staphylococcus aureus vaccines 1161
. Q$ c2 {2 q9 |* |+ [58 Streptococcus group A vaccines 1169
: d" i. q# G- x8 ^0 k59 Streptococcus group B vaccines 1176, V5 T: C+ O9 X- @5 b
60 Technologies for making new vaccines 1182; Z/ v" t% D! o9 K  Y. F8 x- ?0 v. k
61 Alternative vaccine delivery methods 1200
/ B% R$ z- X$ j/ ?62 The development of gene-based vectors for immunization 1232! Z/ B! y* u9 u4 K* Y6 }! I
SECTION 4: Vaccination of special groups$ R; x& T  z6 |) L; L
63 Vaccination of immunocompromised hosts 1243" |$ N" h7 m: b# X$ D! {
64 Vaccination of human immunodeficiency virus-infected persons 1257, [& Z; ]; J6 G
65 Vaccines for international travel 1270
" o( F, M' n. g; l- A66 Vaccines for health care personnel 1290
% K& J7 G! s6 g, S. K+ N/ d1 qSECTION 5: Public health and regulatory issues
: |* Y' c7 f# e67 Immunization in the United States 1310
% }( ^$ o9 f! u# U& C% Z" l! P! _68 Immunization in Europe . 1334
  Z+ E0 p( {! b6 k69 Immunization in the Asia-Pacific region 1353
7 P% F! b" n2 R7 H70 Immunization in developing countries 1369
; c3 {: \$ o1 c9 ?8 P+ q71 Community immunity 1395
, a% c: U$ n. }) i' p' Y9 @3 v72 Economic analyses of vaccine policies 1413  L' O8 V1 [' c- p# Z9 }6 L5 Y* g
73 Regulation and testing of vaccines 1427
5 o' v; F1 a# }1 [74 Regulation of vaccines in Europe 14479 }; \1 F% R+ m4 m
75 Regulation of vaccines in developing countries 1454, p+ w0 x* _3 O
76 Vaccine safety 14642 ~- g. r7 ^; |# C4 S0 Z
77 Legal issues . 1481: y  ?& v9 F. ?6 {7 l& F3 U
78 Ethics 1508
1 G. D7 u7 ~/ M. o; [5 Q7 y
; ^0 U2 p9 l' i( r0 Q& m; F' w- m
8 t; k6 ^9 g- R1 n8 ~' x2 Q# n  e; |  r+ e- p

5 N6 ~9 |8 X. r# g
分享到:  QQ好友和群QQ好友和群 QQ空间QQ空间 腾讯微博腾讯微博 腾讯朋友腾讯朋友
收藏收藏 分享分享 支持支持 反对反对

7

帖子

2

学分

357

金币

病毒学院小学生

Rank: 2Rank: 2

积分
2
沙发
发表于 2015-7-26 14:55:58 | 只看该作者
非常感谢

36

帖子

27

学分

3544

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
27
板凳
发表于 2015-8-13 17:54:21 | 只看该作者
谢谢分享

36

帖子

27

学分

3544

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
27
地板
发表于 2015-8-13 17:55:46 | 只看该作者
怎么看不到相关下载呀

1067

帖子

1032

学分

1万

金币

管理员

Rank: 9Rank: 9Rank: 9Rank: 9

积分
1032
QQ
5#
 楼主| 发表于 2015-8-13 21:26:48 | 只看该作者

, X8 L/ z- {0 W) j* _Vaccines, 6th Edition
) d- ?9 h  k; N" A% V+ d" j, D3 R( d1 K0 e3 ?0 Q  ~' O% @
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.1 w& b8 t% F( l# L7 F1 Q% X
* R- I% G& b- l, M9 E9 |" F7 ~
http://yun.baidu.com/share/link? ... 1&uk=3810996606+ a, s8 O/ n9 v( s: l

* j' L/ H5 L5 V" pSECTION 1: General aspects of vaccination
# b" n$ c6 i7 m& {0 L" c4 X1 A short history of vaccination 17 k0 l9 o0 j# H7 c/ w
2 Vaccine immunology 149 }( M# P) `& p
3 The vaccine industry 33
1 r0 k8 \% E7 D- U2 C4 Vaccine manufacturing 44
! T4 ?: @1 W1 P% u! K! o+ H5 Evolution of adjuvants across the centuries 58
" k( \" d% r( c6 V6 Vaccine additives and manufacturing residuals in the United States:& R1 H) U0 N* Z/ B; D' D% f
licensed vaccines 715 u6 x) E, V- h1 Z
7 Passive immunization 80. D3 O3 B% ]0 w6 A) d
8 General immunization practices 88
# a* ~, A7 c. D. fSECTION 2: Licensed vaccines
& m- E" |9 @( t7 c8 e9 J3 n  h6 }9 Adenovirus vaccines 113  ]$ W$ s3 P* e% E" G
10 Anthrax vaccines 127
( p; W" K6 B& z11 Cholera vaccines 141
4 M( o# R9 G( M4 m( n! I, a+ w, H12 Diphtheria toxoid 153
/ E( `1 q8 k! e6 b8 C4 I) v13 Haemophilus influenzae vaccines 167
2 c( z' J$ P4 y, E5 [1 `% ~3 \' d14 Hepatitis A vaccines 183
3 Z; U* M! }/ p% G$ Y  p15 Hepatitis B vaccines 2050 t4 w+ K" y) d/ o; J7 y: Q9 y' h
16 Human papillomavirus vaccines 235
  l# _7 M8 m# A' J) V' S4 E17 Inactivated influenza vaccines 257
, j" n3 Y3 q/ w; @4 H18 Influenza vaccine-live 294
2 ~* B$ ^" z8 G% L0 [# I* [19 Japanese encephalitis vaccines 312
  C. F) X6 A9 {! o; c& q2 Y+ F1 J  k20 Measles vaccines 352
2 L  v6 s, R; G8 p, c/ X  A21 Meningococcal vaccines 388$ A* X" F! F, u* A3 L
22 Mumps vaccine 4197 q4 {$ ^, ^6 J6 j# k
23 Pertussis vaccines . 447& \" D& w$ M9 a- j" i' M/ `' d1 Q. p
24 Plague vaccines 493
$ o* T8 H" i3 A9 U25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504# R* O, y1 X9 w. X  V% m
26 Pneumococcal polysaccharide vaccines 542
: Z6 m7 m8 j* B0 ]) Y27 Poliovirus vaccine-inactivated . 573
! N- n- h( _2 x28 Poliovirus vaccine-live 598
7 A% {7 F* A1 O29 Rabies vaccines .6462 [4 Y% a2 H% e
30 Rotavirus vaccines . 669
* z/ i% X  i* t# S# N& q& M# Z31 Rubella vaccine 6884 D2 Q1 x( a6 A/ a! f! p' w
32 Smallpox and vaccinia 718& Q5 \* `! r' `9 p+ {2 }  y- ]) u7 _
33 Tetanus toxoid 746
& `$ d" _) ?( u, f34 Tick-borne encephalitis virus vaccines 773
7 J  V* a& e3 V0 B, B0 z3 p. _5 d+ R35 Tuberculosis vaccines 789$ n, U9 r/ H6 E1 ~  w) k
36 Typhoid fever vaccines 812) ~0 w# J/ X& V5 n: B, H) W6 ~
37 Varicella vaccine 837
' H+ y/ C+ F" K" z1 q5 I: |- c0 m; s38 Yellow fever vaccine 870, S$ s4 A' p; \+ m
39 Zoster vaccine 969
' ?7 b6 r3 ^& F7 z40 Combination vaccines 981
0 E- G; M& C, }- o2 T( uSECTION 3: Vaccines in development and new vaccine strategies
0 p$ ~: _9 r. f4 A  S41 Biodefense and special pathogen vaccines 1008
" y2 |$ p1 Q/ Q0 L5 \2 p42 Therapeutic cancer vaccines 1018* X8 b; `* w* R* l4 H# }- V
43 Cytomegalovirus vaccines 1032
/ @/ v3 c; a1 s: \, K44 Dengue vaccines 1042  O" W& W0 R  d) A# M6 L" X
45 Diarrhea caused by bacteria 1052/ i% k2 U/ U, k' ]: Q
46 Ebola vaccine 1060; j& ~2 Y' a5 o5 \; }+ J) D
47 Epstein-Barr virus vaccines 1068
' e8 ?2 C, }3 u" `- b48 Hepatitis C vaccines 1074
( O+ }' d. [& V49 Hepatitis E vaccines 1085
5 |+ R# |& _5 Y0 G9 `* `50 Herpes simplex virus vaccines 1090
. Q& _' ?* n3 C9 d51 Human immunodeficiency virus vaccines 1097& M' ^& f, b( ~+ `) ]
52 Lyme disease vaccines 11222 A; K- }" K4 Z7 s' \" W$ M3 X
53 Malaria vaccines 1133
7 M% v' s, J2 C, t1 G6 b54 Noninfectious disease vaccines 1138
; V9 ~; W6 ?1 q  o4 Q8 T55 Respiratory syncytial virus and parainfluenza virus vaccines 11464 v& G1 X# [' U+ s" I
56 Parasitic disease vaccines 1154
1 o/ z: ?7 d: m8 P! H2 Z, K; I# T57 Staphylococcus aureus vaccines 1161
- W* K; ~9 g8 e/ [3 a2 e  X58 Streptococcus group A vaccines 1169
% Z: g9 |8 s4 G8 K. v2 ]59 Streptococcus group B vaccines 11764 ]7 f- g" @1 R3 J' [
60 Technologies for making new vaccines 11824 C! G4 g- L: D* o; f
61 Alternative vaccine delivery methods 12008 G5 `' Q, g7 `# }! m6 @4 T
62 The development of gene-based vectors for immunization 1232, m5 V% ^6 w; r  ]( _1 I' D4 ~9 @
SECTION 4: Vaccination of special groups# X6 ^5 a# U6 `/ F  P# J( C$ v# \
63 Vaccination of immunocompromised hosts 1243
/ r# B3 C4 d6 S8 J) b64 Vaccination of human immunodeficiency virus-infected persons 1257) m" ?, x* _5 v, p
65 Vaccines for international travel 1270; X9 j3 L, {/ Q  Q7 C# {: e
66 Vaccines for health care personnel 1290
6 K2 ]% L/ \5 D' TSECTION 5: Public health and regulatory issues
  x( \* f: P+ [7 ~4 b67 Immunization in the United States 1310
, R, {# k& u' z5 {& |) X! l) d68 Immunization in Europe . 13341 v6 w( m) n! Z3 h. @. r, k
69 Immunization in the Asia-Pacific region 1353
+ K6 N0 ^( E( |) U70 Immunization in developing countries 13695 b/ J+ R/ x% n6 X2 ^( C  y
71 Community immunity 1395
. P! P& F8 o% X8 J3 X  B1 B72 Economic analyses of vaccine policies 1413# a8 j  j" w5 m; z
73 Regulation and testing of vaccines 1427
# v0 |% X9 e8 L( {; z- U74 Regulation of vaccines in Europe 1447
9 f  Q. ?8 z( N) l& C8 @75 Regulation of vaccines in developing countries 1454% ?! A3 P8 O1 N+ A! c' X
76 Vaccine safety 1464( Z8 [7 ^  v, c5 I$ x
77 Legal issues . 14818 _8 w% V2 @# R/ X7 V
78 Ethics 1508; k  b, D$ @& D+ L, r6 G5 I% q
2 V" X: o/ V) K3 }$ n

8 U9 ~. N; q$ q0 L9 l% t  G9 L. H1 G

23

帖子

39

学分

5741

金币

病毒学院中学生

Rank: 3Rank: 3Rank: 3

积分
39
6#
发表于 2017-5-2 15:25:27 | 只看该作者
Vaccines, 6e, 2012
* V; v0 h$ d% F$ @# Q% {  X& I
+ r, h) N3 ?1 eHardcover: 1570 pages' j9 t* ?! Q$ y! H! C3 P
Publisher: Saunders; 6 edition (October 30, 2012), a; n( X, M( W7 I2 a: p3 z
Language: English1 [' i: r; @" b' ?7 q1 @( M, z
ISBN-10: 1455700908
: H/ F: t+ L2 ?0 l+ l: KSize: 52.3mb (original pdf)( Z5 h# Q% c  V+ a4 p) X
" {; {0 k/ D  [( G4 A3 X
2013 BMA Medical Book Awards Highly Commended in Public Health!7 v# d9 L" y% s3 c, Y( h
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!
$ Z" D: e) r' W  J. W6 x# M! a7 C( _% J! k# R9 h$ E
Gain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.$ g2 Q, c( M3 \: b
Update your knowledge of both existing vaccines and vaccines currently in the research and development stage." t1 Y  G5 g% o6 ]* {
Get complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.( b) L* D2 X" t8 T; i1 S2 H
Analyze the cost-benefit and cost-effectiveness of different vaccine options.
6 u# f. @4 ?( m) A, }Clearly visualize concepts and objective data through an abundance of tables and figures.
1 u. X3 S% l/ S5 m3 E3 I) j. p' pPerform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com.
. d. D* a  P' r- l, qMake optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
$ s1 @6 w2 N, {4 k' n: MStay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.
/ T9 U9 l' T8 x9 a  Q4 ^  ~
1 _( o1 m* I- u3 i6 m$ g' X) UDownload link: http://pan.baidu.com/s/1i5NxwLR % k% ^) {- H  q3 Q. T' A% P
Code for downloading: dv96
# t  B' l4 m1 `+ R" a3 o. ~
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

QQ|论坛App下载|Archiver|小黑屋|中国病毒学论坛    

GMT+8, 2024-6-2 12:06 , Processed in 0.192020 second(s), 29 queries .

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表